**Highlights of This Issue**

**SPECIAL FEATURES**

**CCR Translations**

3719  
**Mind the Gap: Potential for Rebounds during Antiangiogenic Treatment Breaks**  
John M.L. Ebos and Roberto Pili  
*See article p. 3961*

**CCR Perspectives in Drug Approval**

3722  
**Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary**  

**Statistics in Clinical Cancer Research**

3731  
**Cure Models as a Useful Statistical Tool for Analyzing Survival**  
Megan Othus, Bart Barlogie, Michael L. LeBlanc, and John J. Crowley

**CCR Drug Updates**

3737  
**Crizotinib for ALK-Rearranged Non–Small Cell Lung Cancer: A New Targeted Therapy for a New Target**  
Leena Gandhi and Pasi A. Jänne

**Molecular Pathways**

3743  
**Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and Limitations**  
Jeyanthi Eswaran, Da-Qiang Li, Anil Shah, and Rakesh Kumar

**Review**

3750  
**Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience**  
Victor Moreno Garcia, Bristi Basu, L. Rhoda Molife, and Stan B. Kaye

**HUMAN CANCER BIOLOGY**

3762  
**Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact**  
Mário Henrique M. Barros, Rocio Hassan, and Gerald Niedobitek

3772  
**Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-cell Leukemia/Lymphoma**  
Yu Sawada, Motonobu Nakamura, Rieko Kabashima-Kubo, Takatoshi Shimauchi, Miwa Kobayashi, and Yoshiki Tokura

3780  
**FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma**  
Lisa E.S. Cross, Katherine T. Etheridge, Candy Chen, Brian Belyea, Lindsay J. Talbot, Rex C. Bentley, and Corinne M. Linardic

3791  
**Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia**  
Jennifer R. Brown, Megan Hanna, Bethany Tesar, Lillian Werner, Nathalie Pochet, John M. Asara, Yaoyu E. Wang, Paolo dal Cin, Stacey M. Fernandes, Christina Thompson, Laura MacConaill, Catherine J. Wu, Yves Van de Peer, Mick Correll, Aviv Regev, Donna Neuberg, and Arnold S. Freedman
Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas
Luigi Scotto, Marianna Kruthof-de Julio, Luca Paoluzzi, Matko Kalac, Enrica Marchi, Jairo Baquero Buitrago, Jennifer Amengual, Michael M. Shen, and Owen A. O'Connor

Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia
Laura A. Vitale, Li-Zhen He, Lawrence J. Thomas, Jennifer Widger, Jeffrey Weidlick, Andrea Crocker, Thomas O’Neill, James Storey, Martin J. Glennie, Deanna M. Grote, Stephen M. Ansell, Henry Marsh, and Tibor Keler

Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy
Clare McCourt, Pamela Maxwell, Roberta Mazzucchelli, Rodolfo Montironi, Marina ScarPELLi, Manuel Salto-Tellez, Joe M. O’Sullivan, Daniel B. Longley, and David J.J. Waugh

Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response
Harvey Wong, Edna F. Choo, Bruno Allicke, Xiao Ding, Hank La, Erin McNamara, Frank-Peter Theil, Jay Tibbetts, Lori S. Friedman, Cornelis E.C.A. Hop, and Stephen E. Gould

Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206
Eric Sanchez, Mingjie Li, Cathy Wang, Cydney M. Nichols, Jennifer Li, Haiming Chen, and James R. Berenson
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3934</td>
<td>Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma</td>
<td>Jordan Madic, Sophie Piperno-Neumann, Vincent Servois, Aurore Rampanou, Maud Milder, Bénédicte Trouiller, David Gentien, Stéphanie Saada, Franck Assayag, Aurélie Thuleau, Fariba Nennati, Didier Decaudin, François-Clément Biedard, Laurence Desjardins, Pascale Mariani, Olivier Lantz, and Marc-Henri Stern</td>
</tr>
<tr>
<td>3942</td>
<td>A Replication Study and Genome-Wide Scan of Single-Nucleotide Polymorphisms Associated with Pancreatic Cancer Risk and Overall Survival</td>
<td>Jason A. Willis, Sara H. Olson, Irene Orlow, Semanti Mukherjee, Robert R. McWilliams, Robert C. Kurtz, and Robert J. Klein</td>
</tr>
<tr>
<td>3972</td>
<td>Predictive Value of XRCC1 Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis</td>
<td>Junjie Wu, Jie Liu, Yu Hao Zhou, Jun Ying, Houdong Zou, Shicheng Guo, Lei Wang, Naqin Zhao, Jianjun Hu, Daru Lu, Li Jin, Qiang Li, and Jiu-Cun Wang</td>
</tr>
<tr>
<td>3982</td>
<td>Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients</td>
<td>Moubin Lin, Jian Gu, Cathy Eng, Lee M. Ellis, Michelle A. Hildebrandt, Jie Lin, Maozheng Huang, George A. Calin, Dingzhi Wang, Raymond N. Dullois, Ernest T. Hawk, and Xinfeng Wu</td>
</tr>
<tr>
<td>3992</td>
<td>Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients</td>
<td>Moubin Lin, Jian Gu, Cathy Eng, Lee M. Ellis, Michelle A. Hildebrandt, Jie Lin, Maozheng Huang, George A. Calin, Dingzhi Wang, Raymond N. Dullois, Ernest T. Hawk, and Xinfeng Wu</td>
</tr>
<tr>
<td>3998</td>
<td>Correction: A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck</td>
<td>Jiu-Cun Wang</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

The inhibition of androgen signaling is a major therapeutic strategy in prostate cancer; however, response is often transient, and patients ultimately relapse on therapy giving rise to a currently incurable condition known as castrate-resistant prostate cancer (CRPC). McCourt and colleagues show elevated expression of the androgen-regulated antiapoptotic protein c-FLIP in prostate cancer, which is further elevated in CRPC. Repression of c-FLIP induced apoptosis in non–castrate-resistant and CRPC cells and potentiated sensitivity to AR-targeted therapy, indicating that prostate cancer cells require c-FLIP to maintain viability. Consequently, targeting c-FLIP may represent a novel strategy to improve therapeutic response to the novel antiandrogen strategies under clinical development in CRPC. For details, see the article by McCourt and colleagues on page 3822 of this issue.